Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials
Parabilis Medicines, Inc. has initiated its IPO, focusing on innovative cancer therapies. The company is advancing its lead candidate, zolucatetide, which has shown promising results in early clinical trials. Regeneron Pharmaceuticals is backing the IPO with a significant investment, enhancing the company's financial runway.
- ▪Parabilis Medicines is developing Helicon peptide-based cancer treatments.
- ▪The lead candidate, zolucatetide, has demonstrated strong safety and efficacy in clinical trials.
- ▪The company is targeting desmoid tumors and other cancers with a multi-indication pipeline.
- ▪Regeneron Pharmaceuticals is investing $75 million in a concurrent private placement.
Seeking Alpha files mainly under finance. We currently carry 6,469 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"IPO Analysis","item":"https://seekingalpha.com/stock-ideas/ipos"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908000-parabilis-medicines-starts-ipo-on-promising-cancer-therapy-trials"},"author":{"@type":"Person","name":"Donovan…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
